
Background and Job
Vertex operates at the forefront of scientific innovation and has successfully developed and commercialized multiple breakthrough medicines for Cystic Fibrosis (CF), Casgevy, a gene therapy for sickle cell disease and beta-thalassemia and Journavx, a novel new treatment for moderate to severe acute pain. Vertex has more than a dozen ongoing research programs focused on the underlying mechanisms of other serious diseases including programs in kidney diseases, Type 1 diabetes, among others.
Vertex is investigating and advancing cell therapies aimed at treating an underlying cause of T1D — the absence of insulin-producing cells. For over 100 years, improvements in insulin and technologies for insulin management have helped people with T1D manage their condition. However, there are very few approved treatments that address a root cause of T1D — the absence of insulin-producing cells in the pancreatic islets.
Our investigational approach is to replace the insulin-producing cells that have been destroyed in people with T1D. We’re evaluating multiple approaches to deliver our proprietary, fully-differentiated, insulin-producing cells.
Market Access is a key commercial function that ensures transformative Vertex therapies are appropriately funded and ultimately make it into the hands of the patients around the world. GVAS works cross-functionally and across regions to ensure the payer view is represented in commercial and development plans across the lifecycle. We are driven by a desire to deliver groundbreaking pricing & reimbursement solutions to allow our medicines to reach patients faster than ever before.
The Director, T1D will serve as a T1D Market Access Lead within our Cell and Gene Therapy (CGT) portfolio in the Global Value and Access Strategy (GVAS) team.
The individual will be responsible for leading the development of Global Market Access strategies for early-stage pipeline assets in the T1D portfolio, ensuring enterprise planning to enable optimal patient access.
In this capacity, the individual will help to inform development of T1D prioritization/portfolio strategy and ultimately the commercial strategy, to ensure price and access success. This individual will lead the assessment of price/access potential and key considerations such as indication/launch sequencing for these new indications in close collaboration with cross-functional and regional access colleagues.
This role will also contribute to cross-portfolio capability building and thought leadership projects that advance knowledge of and readiness for the rapidly evolving Global payer environment.
This position reports to the Senior Director, Cell and Gene Therapy within GVAS.
Key Responsibilities:
Qualifications:
Education:
Pay Range:
$212,000 - $318,000
Disclosure Statement:
The range provided is based on what we believe is a reasonable estimate for the base salary pay range for this job at the time of posting. This role is eligible for an annual bonus and annual equity awards. Some roles may also be eligible for overtime pay, in accordance with federal and state requirements. Actual base salary pay will be based on a number of factors, including skills, competencies, experience, and other job-related factors permitted by law.
At Vertex, our Total Rewards offerings also include inclusive market-leading benefits to meet our employees wherever they are in their career, financial, family and wellbeing journey while providing flexibility and resources to support their growth and aspirations. From medical, dental and vision benefits to generous paid time off (including a week-long company shutdown in the Summer and the Winter), educational assistance programs including student loan repayment, a generous commuting subsidy, matching charitable donations, 401(k) and so much more.
Flex Designation:
Hybrid-Eligible Or On-Site Eligible
Flex Eligibility Status:
In this Hybrid-Eligible role, you can choose to be designated as:
1. Hybrid work remotely up to two days per week; or select
2. On-Site work five days per week on-site with ad hoc flexibility.
Note: The Flex status for this position is subject to Vertex’s Policy on Flex @ Vertex Program and may be changed at any time.
#LI-Hybrid
Company Information
Vertex is a global biotechnology company that invests in scientific innovation.
Vertex is committed to equal employment opportunity and non-discrimination for all employees and qualified applicants without regard to a person's race, color, sex, gender identity or expression, age, religion, national origin, ancestry, ethnicity, disability, veteran status, genetic information, sexual orientation, marital status, or any characteristic protected under applicable law. Vertex is an E-Verify Employer in the United States. Vertex will make reasonable accommodations for qualified individuals with known disabilities, in accordance with applicable law.
Any applicant requiring an accommodation in connection with the hiring process and/or to perform the essential functions of the position for which the applicant has applied should make a request to the recruiter or hiring manager, or contact Talent Acquisition at ApplicationAssistance@vrtx.com

Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases and have made significant advancements in multiple chronic, life-shortening genetic diseases — cystic fibrosis, sickle cell disease and transfusion-dependent beta thalassemia — and continue to progress clinical and research programs in these diseases. We also have a robust clinical pipeline of investigational therapies across a range of modalities in other serious diseases where we have deep insight into causal human biology, including acute and neuropathic pain, APOL1-mediated kidney disease, IgA nephropathy, autosomal dominant polycystic kidney disease, type 1 diabetes, myotonic dystrophy type 1 and alpha-1 antitrypsin deficiency.
Our global HQ is in Boston, and we have research and development (R&D) sites and commercial offices worldwide.
Vertex is consistently recognized as one of the industry’s top places to work by Science Magazine, The Boston Globe, Boston Business Journal and the San Diego Business Journal. We have also earned a spot on TIME Most Influential Companies, TIME Best Inventions, and Fast Company Most Innovative Companies lists. Our research and medicines have received esteemed recognitions, including the Robert J. Beall Therapeutics Development Award, the Prix Galien, the Scrip Award and the Breakthrough Prize awards.
Read our community guidelines: https://www.vrtx.com/vertexs-community-guidelines/